Los Alamos lab licences unique pathogen detector to Biomagnetics
21 January 2010
Los Alamos National Laboratory (LANL) has licensed
Biomagnetics Diagnostics Corporation (BMGP) to further develop a
reagentless pathogen biosensor.
LANL, which developed the prototype bench-top and hand-held
biosensors for the detection of human and animal pathogens, has provided Biomagnetics with a nonexclusive, field-of-use patent license agreement
to expand the Laboratory’s Triggered Optical Biosensor and Integrated
Optical Biosensor System (IOBS) technology.
The triggered optical biosensor is based on protein-receptor binding
that brings two or more optically tagged receptors into close proximity
using planar optical waveguides, thereby triggering fluorescence changes
identified almost instantly by tiny on-board detectors.
These devices are specifically designed to be battery operated and
ultraportable, allowing for the rapid detection of various viral and
bacterial pathogens by relatively untrained personnel outside of the
laboratory setting. The technology is capable of detecting multiple
pathogens from a single blood sample.
Los Alamos originally developed the concept of a reagent-less,
laser-based system for homeland security purposes, aiming to allow first
responders to rapidly identify toxins and pathogens in the field.
Broader applications, such as disease diagnostics, blood bank
screening and hospital use, offer commercial partners an interesting
opportunity, said LANL Technology Transfer representative David Hadley.
“We are excited to have Biomagnetics as a commercialization partner
for Los Alamos National Security, LLC’s IOBS technology. Executing the
license agreement is the first phase of our relationship and we look
forward to expanding it with a formal collaboration to further develop
the IOBS technology,” Hadley said.
For more information on licensing the technology see: